Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat +/- DA-EPOCH-R in Relapsed/Refractory DLBCL
NCT01415765Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jul 2011
- Primary completion
- Jan 2014
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of pevonedistat in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Primary endpoints: Response of MLN4924 in relapsed/refractory DLBCL at 4 years, Toxicity and safe tolerated dose of MLN4924 and DA-EPOCH-R at 4 years and 1 more. Planned start Jul 2011; status: withdrawn.
02
Drugs
pevonedistat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01415765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01415765.